MGD management needed for ocular prosthesis wearers

Article

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD).

Ocular prosthesis wearers may require clinical assessment and management for meibomian gland dysfunction (MGD), states the latest paper in the British Journal of Ophthalmology.

A team headed by Dr Jin Sook Yoon, Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Korea, assigned a survey to 30 consecutive patients with unilateral ocular prosthesis to identify MGD-related ocular symptoms.

All patients underwent slit lamp examination, meibography imaging and Fourier-domain (FD) optical coherence tomography (OCT) scanning on both eyelids. The main outcome measures were assessed using intra-individual comparison between the eyelids of a prosthetic eye and paired normal eyelids.

Eyelids with ocular prosthesis presented with significantly higher scores for ocular symptoms, lid margin abnormality, meibomian gland expression and meibography compared to normal eyelids.

Tear parameters in the eyelids with prosthetic eyes were significantly lower than normal eyelids. Overall ocular symptom score was significantly positively correlated with meibography score and negatively associated with tear parameters. Clinical evaluation and management recommendations for MGD would highly benefit patients with prosthetic eyes, especially those demonstrating ocular discomfort.

Please click here to read the abstract.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.